FINHUB Insights

SYK · Q3 FY25 · Jul 1 – Sep 30, 2025

Stryker Q3 FY25: where the revenue came from and where it went

Stryker Q3 FY25: revenue $6.1B (+10% year over year). Net profit $0.9B. Largest cohort Med Surg and Neurotechnology $3.8B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Oct 31, 2025 10-Q
Sankey diagram of Stryker's income statement for Q3 FY25: revenue of $6.1 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$6.1B +10% year over year
Gross profit$3.9B 64% margin
Operating profit$1.1B 19% margin
Net profit$0.9B 14% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 6.1 100% +10%
Med Surg and Neurotechnology 3.8 62% +14%
Orthopaedics and Spine 2.3 38% +4%
Cost of revenue−2.236%
Gross profit3.964% margin+0pp
Research & development−0.47%+0pp
SG&A−234%−1pp
Other−0.34%+0pp
Operating profit1.119% margin−1pp
Tax−0.1
Interest & other costs−0.1
Net profit0.914%−1pp
Filing on EDGAR More quarters of SYK

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters